AGP
JANX icon

Artia Global Partners’s Janux Therapeutics JANX Stock Holding History

Artia Global Partners’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-20,000
Closed -$462K – 52
2025
Q2 		$462K Sell
20,000
-18,100
-48% -$477K 0.11% 36
2025
Q1 		$1.03M Sell
38,100
-124,876
-77% -$4.71M 0.26% 31
2024
Q4 		$8.73M Buy
+162,976
New +$8.62M 3.12% 16
2024
Q2 		– Sell
-47,949
Closed -$1.81M – 52
2024
Q1 		$1.81M Buy
+47,949
New +$1.04M 0.36% 29

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Artia Global Partners's JANX Position: Q3 2025 in Review

Artia Global Partners sold out of Janux Therapeutics (JANX) in Q3 2025, closing a stake of 20,000 shares — an estimated $462K sold.

Artia Global Partners first reported a position in JANX in Q1 2024 and held it in 4 quarters. The position peaked at $8.73M in Q4 2024. 174 funds tracked by Wall St. Rank hold JANX as of Q3 2025.

  • Artia Global Partners reported no remaining Janux Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Artia Global Partners sold 20,000 Janux Therapeutics shares in Q3 2025, an estimated $462K.
  • Artia Global Partners first reported a position in Janux Therapeutics in Q1 2024 and held it in 4 quarters.
  • Artia Global Partners's Janux Therapeutics position peaked at $8.73M in Q4 2024.
  • 174 funds tracked by Wall St. Rank held Janux Therapeutics as of Q3 2025.

Based on Artia Global Partners's 13F filing for Q3 2025, filed 14 Nov 2025.